Doxycycline Hyclate Tablet, Delayed Release
NDC Package 62332-481-91
Package Information
Doxycycline Hyclate tablets is doxycycline hyclate delayed-release tablet is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. This formulation utilizes a tablet, delayed release delivery system. Marketed by Alembic Pharmaceuticals Inc., this product is identified by NDC 62332-481 and is authorized under FDA application ANDA213075.
Identification & Billing
- RxCUI: 1423080 - doxycycline hyclate 200 MG Delayed Release Oral Tablet
- RxCUI: 406524 - doxycycline hyclate 75 MG Delayed Release Oral Tablet
- RxCUI: 434018 - doxycycline hyclate 100 MG Delayed Release Oral Tablet
- RxCUI: 799048 - doxycycline hyclate 150 MG Delayed Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62332 - Alembic Pharmaceuticals Inc.
- 62332-481 - Doxycycline Hyclate
- 62332-481-91 - 1000 TABLET, DELAYED RELEASE in 1 BOTTLE
- 62332-481 - Doxycycline Hyclate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (62332-481). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62332-481-91 identifies a specific commercial package of 1000 tablet, delayed release in 1 bottle of Doxycycline Hyclate, a human prescription drug labeled by Alembic Pharmaceuticals Inc.. This tablet, delayed release is formulated for oral use and contains doxycycline hyclate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alembic Pharmaceuticals Inc. on January 04, 2022. The current certification is valid through December 31, 2027.
How is this Alembic Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62332048191. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.